Amneal Pharmaceuticals Inc. has announced that it received approval from the U.S. Food and Drug Administration (FDA) for its prednisolone acetate ophthalmic suspension, 1% sterile, which is a reference to Pred Forte®. This product, designed to treat steroid-responsive ocular inflammation, is part of Amneal's Affordable Medicines segment. The commercial launch is scheduled for the third quarter of 2025. Andy Boyer, Executive Vice President and Chief Commercial Officer of Affordable Medicines, highlighted the approval as a testament to Amneal's R&D capabilities and manufacturing strength. The U.S. market for this product is significant, with annual sales reaching approximately $201 million as of April 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。